Top Page
Aiml Resources
(AIML)
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Aiml Resources Business Overview & Revenue Model
Aiml Resources Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 167.31K | 167.31K | 600.14K | 487.50K | 65.41K | 0.00 |
| Gross Profit | 162.81K | 162.81K | 294.86K | 466.01K | 65.41K | 0.00 |
| EBITDA | -4.08M | -4.85M | -1.67M | -1.36M | -3.42M | -1.43M |
| Net Income | -4.65M | -4.59M | -3.29M | -1.42M | -3.17M | -2.73M |
Balance Sheet | ||||||
| Total Assets | 3.41M | 3.41M | 329.69K | 1.51M | 2.04M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 2.00M | 216.86K | 14.56K | 525.24K | 3.49M |
| Total Debt | 198.19K | 198.19K | 197.72K | 859.98K | 261.34K | 320.29K |
| Total Liabilities | 855.77K | 855.77K | 1.54M | 1.79M | 1.55M | 1.51M |
| Stockholders Equity | 2.60M | 2.60M | -1.17M | -247.46K | 1.08M | 2.31M |
Cash Flow | ||||||
| Free Cash Flow | -3.99M | -3.99M | -1.64M | -634.28K | -3.02M | -959.00K |
| Operating Cash Flow | -3.99M | -3.99M | -1.64M | -634.28K | -3.02M | -931.35K |
| Investing Cash Flow | -1.15K | -1.15K | -325.98K | -210.64K | -1.14M | -11.38K |
| Financing Cash Flow | 5.78M | 5.78M | 2.16M | 374.37K | 1.27M | 4.17M |
Aiml Resources Technical Analysis
Aiml Resources Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$36.16M | ― | 366.78% | ― | -47.10% | -19.32% | |
45 Neutral | C$10.57M | ― | -1143.80% | ― | -64.23% | 18.42% | |
44 Neutral | C$11.13M | ― | 2.18% | ― | 12.44% | 74.38% | |
34 Underperform | C$12.98M | ― | -9999.00% | ― | ― | 21.61% | |
34 Underperform | $56.27M | ― | -202.19% | ― | ― | 40.17% |
Aiml Resources Corporate Events
AI/ML Innovations Inc.’s subsidiary, Neural Cloud Solutions, has signed a Letter of Intent with Circular Health Limited to license its MaxYield™ ECG signal-processing platform. This collaboration aims to enhance Circular Health’s smart ring with AI-powered ECG signal clarity, targeting a commercial launch by September 2025. The partnership is expected to improve the quality of ECG signals, increase data usability, and provide deeper biometric insights, positioning both companies for global growth in AI-enhanced cardiac monitoring and next-gen health intelligence.
AI/ML Innovations Inc. has established an Innovation Committee to enhance its regulatory strategy, intellectual property development, and product innovation within its AI-driven health-tech portfolio. Dr. Drew Dundas, a seasoned expert in medical-device innovation, has been appointed as the Chair of this committee. This strategic move is expected to strengthen AIML’s governance and position the company to deliver sustained value to clinicians, partners, and shareholders by ensuring that its technology has a global clinical impact.
AI/ML Innovations Inc. has established a Medical Advisory Board composed of leading cardiovascular experts to guide the clinical studies, regulatory strategy, and global adoption of its AI-driven ECG signal-processing solutions, MaxYield™ and CardioYield™. This strategic move aims to integrate clinical insights into AIML’s operations, enhancing product development and commercialization strategies. The company also launched a redesigned corporate website to serve as an interactive hub for stakeholders. The establishment of the board underscores AIML’s commitment to advancing AI-enhanced cardiac diagnostics and expanding its market presence.
AI/ML Innovations Inc. has submitted a 510(k) premarket notification to the U.S. FDA for its MaxYield™ platform, a cloud-native API designed to enhance ECG signal quality across various care settings. This milestone aims to improve ECG signal interpretation by reducing noise and improving waveform clarity, potentially allowing for seamless integration into digital health ecosystems. The submission builds on AIML’s previous FDA Device Master File, which could facilitate future collaborations with device manufacturers. Additionally, AIML has granted 800,000 stock options to certain directors and consultants, reflecting its ongoing commitment to innovation in AI-driven healthcare solutions.
AI/ML Innovations Inc. has appointed Michael Diamond, a prominent political strategist and public affairs leader, to its Board of Directors. This move is expected to enhance AIML’s strategic capabilities as it seeks to expand its AI-powered health technologies globally. Diamond’s expertise in public policy and business development is anticipated to help AIML navigate complex regulatory environments and form new partnerships, reinforcing the company’s commitment to growth and innovation in the AI healthcare sector.
AI/ML Innovations Inc. has restructured its acquisition agreement with Quantum Sciences Ltd. to enhance capital efficiency and simplify its revenue structure. The revised terms include a reduction in consideration shares, nullification of previously agreed royalties, and a new revenue-sharing agreement. This restructuring aligns with AIML’s strategic focus on AI-powered health solutions, aiming to streamline operations and concentrate resources on high-growth areas, thereby improving flexibility for future investments and partnerships.
AI/ML Innovations Inc. announced the departure of Tim Daniels from its Board of Directors, effective immediately. Daniels, who has been instrumental in guiding the company’s strategic direction and growth, will continue to support AIML in an advisory role. This change is part of AIML’s efforts to strengthen its leadership and advisory network to support its commercialization and strategic growth initiatives in AI-driven healthcare.
AI/ML Innovations Inc. has appointed Jared Adelstein to its Board of Directors as part of its strategic growth and commercialization efforts in the AI-powered healthcare sector. This appointment is expected to enhance the company’s governance and leadership, supporting its mission to deliver innovative AI solutions in healthcare and marking a significant step in its growth trajectory.
AI/ML Innovations Inc. has successfully closed an oversubscribed private placement, raising $2,165,900, surpassing its initial target of $2,000,000. The funds will be used for general working capital, and the strong investor participation reflects confidence in the company’s strategic direction. The company also announced modifications to existing warrants, adjusting the exercise price to $0.20, which aligns with its current financial strategies.
AI/ML Innovations Inc. announced a non-brokered private placement offering of up to 40 million units at $0.05 per unit, aiming to raise $2 million. The proceeds will be used for working capital, with each unit consisting of one common share and one warrant, exercisable into a common share at $0.15 over three years. The private placement is subject to necessary approvals, and finder’s fees will be paid to qualified finders.
AI/ML Innovations Inc. announced a proposed non-brokered private placement offering of up to 40,000,000 units at $0.05 per unit, aiming to raise up to $2,000,000. The proceeds will be used for working capital requirements, and the offering is subject to necessary approvals. This move is expected to bolster the company’s financial position and support its strategic initiatives in the AI and ML sectors.
AI/ML Innovations Inc. has announced its strategic exit from Tech2Heal, a France-based digital health company, to focus on the commercialization of its core holdings. This move allows AIML to realign its resources towards its primary subsidiaries, enhancing its market positioning in digital health innovations. The exit agreement involves relinquishing its equity position and board rights in Tech2Heal in exchange for the return of shares and equity, positioning AIML for future collaborations and growth in its core areas.
AI/ML Innovations Inc. has announced significant changes to its Board of Directors to align with its growth and commercialization goals. The appointment of Paul Duffy as Executive Chairman and Peter Kendall to the Board, along with the continued advisory roles of Mark Orsmond and Michael Nemirow, reflects the company’s strategic focus on enhancing its commercialization efforts and driving shareholder value.